Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Change in Account Payables (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Change in Account Payables data on record, last reported at $1.0 million in Q2 2025.

  • For Q2 2025, Change in Account Payables rose 150.7% year-over-year to $1.0 million; the TTM value through May 2025 reached -$1.7 million, up 74.99%, while the annual FY2025 figure was -$1.7 million, 74.99% up from the prior year.
  • Change in Account Payables reached $1.0 million in Q2 2025 per LFCR's latest filing, up from -$3.5 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $13.6 million in Q4 2021 and bottomed at -$12.4 million in Q2 2021.
  • Average Change in Account Payables over 5 years is $28555.6, with a median of -$367500.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: soared 212.34% in 2023, then tumbled 4708.47% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $13.6 million in 2021, then decreased by 18.36% to $11.1 million in 2022, then plummeted by 100.53% to -$59000.0 in 2023, then crashed by 4708.47% to -$2.8 million in 2024, then skyrocketed by 136.8% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $1.0 million in Q2 2025, -$3.5 million in Q1 2025, and -$2.8 million in Q4 2024.